News | March 09, 2012

Boston Scientific Launches Promus Element Stent in Japan

March 9, 2012 — Boston Scientific Corp. announced the launch of the Promus Element everolimus-eluting coronary stent system in Japan. The product was recently approved by the Ministry of Health, Labor and Welfare. It incorporates a platinum chromium (PtCr) alloy with an innovative stent design and an advanced catheter delivery system designed to provide physicians improved drug-eluting stent performance in treating patients with coronary artery disease. The company plans to begin marketing the product immediately in Japan.

"We are very pleased to launch the Promus Element stent system to Japanese physicians and their patients," said Yusuke Naiki, president of Boston Scientific Japan. "This everolimus-based stent system complements our broad coronary intervention portfolio and reinforces our global leadership in the drug-eluting stent market."

The Promus Element stent uses a proprietary PtCr alloy designed specifically for coronary stenting, which enables enhanced visibility, less recoil, excellent conformability and higher radial strength. It employs an advanced low-profile delivery system to enable precise stent placement across challenging lesions. The everolimus drug and fluorinated copolymer used have been studied in multiple randomized clinical trials and registries. The Promus Element Stent expands Boston Scientific's PtCr drug-eluting stent portfolio in Japan, which also includes the Taxus Element paclitaxel-eluting stent system.

"This approval marks two important milestones for Boston Scientific," said Hank Kucheman, CEO of Boston Scientific. "First, the Promus Element stent platform is now approved in every major market worldwide. Second, we have begun the last phase of our transition to higher margins on our everolimus stent offering as we shift to the internally manufactured Promus Element Stent. Boston Scientific remains the only company to offer physicians a choice of two proven drug and polymer combinations on an innovative coronary stent platform."

The company received CE mark approval for the Promus Element in 2009 and for the Promus Element Plus  in 2011. In the United States, the Promus Element Plus was approved by the U.S. Food and Drug Administration (FDA) in 2011. The Taxus Element paclitaxel-eluting stent received Japan approval in 2011 and CE mark approval in 2010. It is commercialized in the United States. as the Ion paclitaxel-eluting stent, where it received FDA approval in 2011.

Related Content

Resolute Onyx Drug-Eluting Stent Noninferior to Polymer-Free Drug-Coated Stent With One-Month DAPT
News | Stents Drug Eluting | September 30, 2019
The first randomized trial to compare a durable polymer drug- eluting stent to a polymer-free drug-coated stent in...
Biodegradable Polymer Stent Plus Shortened DAPT Safe and Effective in Unprotected Left Main CAD
News | Stents Drug Eluting | September 30, 2019
A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT)...
Superiority of Orsiro Over Xience Demonstrated in STEMI Patients
News | Stents Drug Eluting | September 05, 2019
Biotronik's ultrathin Orsiro stent demonstrated superiority over Xience with respect to target lesion failure (TLF) at...
Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...